London-based Hammer Missions, an AI company innovating how owners, architects, engineers and contractors inspect built structures with drone technology, has raised €1.6 million in new funding to accelerate its AI technology development and strategic expansion into North America.

Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the Board, effective immediately, and Dr Heather Preston has joined the company’s advisory Board.

Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network

CyberSmart is an all-in-one cybersecurity monitoring, optimisation, training and insurance platform proven to help small businesses defend against cyber threats.

Ambugreen is a ground-breaking gel barrier that features unique patented technology.

Momentum Bioscience, a biotech company pioneering rapid sepsis diagnostics, has relocated to Oxfordshire’s Milton Park, the UK’s largest single-ownership innovation community.

Qureight will integrate its deep-learning technology into the study, providing imaging core lab services.

Robotic harvesting specialist appoints Blue River Technology co-founder as new chairman of the board.

Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.

Neuroscience startup Monument Therapeutics has developed MT1988, a novel fixed-dose combination drug for the cognitive impairment associated with schizophrenia.

Nearly 20 subjects in the US are being enrolled for the trial.

Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy).